Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q4 and full year 2021 on February 24, 2022.

Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q4 and full year 2021 on February 24, 2022. The update will include insights into the company’s performance and is expected to be accessible on its website post-market close. Vir specializes in immunology, focusing on serious infectious diseases, using four technology platforms designed to enhance the immune system. Its pipeline includes candidates targeting COVID-19 and other infectious diseases.

Positive

• Plans to report financial results for Q4 and full year 2021 on February 24, 2022.
• Focus on serious infectious diseases with a diverse pipeline targeting COVID-19 and more.

Negative

• None.

Argus Session date unavailable

-0.71% session move Open Argus

Details

News Market Reaction – VIR

The recorded move for VIR in the trading session of this news was -0.71%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.

The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Vir Biotechnology report its Q4 2021 financial results?

Vir Biotechnology will report its Q4 2021 financial results on February 24, 2022.

What is Vir Biotechnology's focus in its development pipeline?

Vir Biotechnology focuses on treating serious infectious diseases, including COVID-19, through its diverse pipeline.

How can investors access Vir Biotechnology's updates?

Investors can access Vir Biotechnology's updates in the Press Releases section on their website.

What technologies does Vir Biotechnology utilize?

Vir Biotechnology utilizes four technology platforms aimed at stimulating and enhancing the immune system.